Neratinib for breast cancer: a meta-analysis of 23 trials

  • Tao Z & al.
  • Clin Drug Investig
  • 28 Oct 2018

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Neratinib, a pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor, was approved by the FDA in 2017 to reduce the risk for recurrence after early HER2+ breast cancer.
  • Across 23 prospective trials, the most common adverse event (AE) was diarrhea, which can be ameliorated by prophylactic loperamide.
  • Neratinib monotherapy is promising, but neratinib plus other therapies has a higher response rate.

Why this matters

  • Neratinib is an important treatment option for HER2+ breast cancer.

Study design

  • Systematic review of safety and efficacy (23 studies; n=4896) and meta-analysis of safety outcomes after a literature search of PubMed, EMBASE, and Web of Science.
  • Funding: None.

Key results

  • Safety meta-analysis found that the most frequent all-grade AEs with neratinib monotherapy were diarrhea (83.9%), nausea (37.9%), and abdominal pain (28.4%; all P=.000).
    • The most frequent grade 3/4 AEs were diarrhea (25.1%; P=.000), dyspnea (5.6%; P=.001), and abnormalities in liver enzymes (4.2%; P=.000).
  • Prophylactic loperamide nonsignificantly reduced the frequency of all-grade diarrhea (61.3% vs 91.3% without loperamide; P=.116) but significantly reduced grade 3/4 diarrhea (22.4% vs 28.0%; P<.001>
  • Neratinib monotherapy had promising objective response rates and PFS in HER2+ BC (4 studies), but they were less promising in HER2-mutated BC.
  • Neratinib combined with other therapies had better response rates than neratinib monotherapy.

Limitations

  • Most included studies were single-arm.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit